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Abstract
Introduction: The aim of the present study was to analyze the expression of matrix metalloproteinase 9 (MMP9) in 
nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including the survival of patients 
with NPC.
Methods: Using real-time PCR, we detected the mRNA expression of MMP9 in normal nasopharyngeal tissues and 
nasopharyngeal carcinoma (NPC) tissues. Using immunohistochemistry analysis, we analyzed MMP9 protein expression 
in clinicopathologically characterized 164 NPC cases (116 male and 48 female) with age ranging from 17 to 80 years 
(median = 48.4 years) and 32 normal nasopharyngeal tissues. Cases with greater than or equal to 6 and less than 6 of 
the score value of cytoplasmic MMP9 immunostaining were regarded as high expression and low expression, 
respectively. The relationship between the expression levels of MMP9 and clinical features was analyzed.
Results: The expression level of MMP9 mRNA was markedly greater in NPC tissues than that in the nasopharyngeal 
tissues. Immunohistochemical analysis revealed that the protein expression of MMP9 detected in NPC tissues was 
higher than that in the nasopharyngeal tissues (P = 0.004). In addition, high levels of MMP9 protein were positively 
correlated with the status of lymph node metastasis (N classification) (P = 0.002) and clinical stage (P < 0.001) of NPC 
patients. Patients with higher MMP9 expression had a significantly shorter overall survival time than did patients with 
low MMP9 expression. Multivariate analysis suggested that the level of MMP9 expression was an independent 
prognostic indicator (P = 0.008) for the survival of patients with NPC.
Conclusion: High level of MMP9 expression is a potential unfavorable prognostic factor for patients with NPC.
Background
Nasopharyngeal carcinoma (NPC) is one of the most
common malignant diseases in the Chinese and other
south-east Asians. Unfortunately, most NPC patients
tend to present a more advanced stage of disease when
first diagnosed due to its deep location and vague symp-
toms. Therefore, it is of great interest to search valuable
factors for early diagnosis, prognosis prediction, and
novel therapeutic strategies.
The formation and metastasis of NPC is a complex and
continuous process with the participation of a number of
k e y  g e n e s  [ 1 ] .  I n  a  p r e v i o u s  s t u d y ,  w e  u s e d  c D N A
microarray to detect differentially expressed genes
among NPC tissues and non-cancerous nasopharyngeal
tissues. By means of the analysis of BRB-array tools, the
expression of MMP9, a gene encoding matrix metallopro-
teinase 9, was shown to be markedly upregulated in NPC
tissues, suggesting a possible role of MMP9 in promoting
the pathogenesis of NPC [2].
MMP9, a member of the matrix metalloproteinases
(MMPs), plays a critical role in breakdown of extracellu-
lar matrix in normal physiological processes, such as
embryonic development, reproduction, and tissue
remodeling, as well as in disease processes, such as tumor
metastasis[3].  MMP9  is secreted from cells and, once
activated, is thought to degrade collagen in the extracellu-
lar matrix, which promotes the metastasis of tumor cells
[4].
In order to clarify the role of MMP9 in the pathogenesis
of NPC, in the present study we investigated the correla-
tion of MMP9 protein expression with clinicopathologic
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features, including the survival of patients. We found that
the mRNA and protein expression levels of MMP9 were
higher in NPC tissues than those in non-cancerous
nasopharyngeal tissues. Furthermore, the relatively
higher protein expression of MMP9 was associated with
NPC progression and poor prognosis. Our results suggest
that overexpressed MMP9 is an unfavorable prognostic
factor for NPC patient's survival.
Materials and methods
Sample collection
Seven primary fresh NPC samples and 5 non-cancerous
fresh nasopharyngeal samples were collected from the
People's Hospital of Zhongshan City, China, at the time of
diagnosis before any therapy. All fresh samples were
immediately preserved in liquid nitrogen. One hundred
and sixty four undifferentiated NPC specimens and 32
non-cancerous nasopharyngeal specimens, both paraffin-
embedded, were obtained from the People's Hospital of
Zhongshan City and the First Affiliated Hospital of
Guangdong Medical School, Zhanjiang City, China. In
the 164 NPC cases, there were 116 male and 48 female
with age ranging from 17 to 80 years (median, 48.4 years).
For the use of these clinical materials for research pur-
poses, prior consents from the patients and approval
from the Ethics Committees of these two hospitals were
obtained. All specimens had confirmed pathological
diagnosis and were staged according to the 1997 NPC
staging system of the WHO.
Real-time PCR
Real-time PCR was performed to measure the expression
of  MMP9  mRNA in 7 fresh NPC tissues and 5 fresh
nasopharyngeal tissues using SYBR Premix Ex Taq
(Takara, Japan) with an Mx3000P real-time PCR system
(Stratagene, La Jolla, CA, USA) as described previously
[5]. The sequence for sense primer was 5'-GAGTG-
GCAGGGGGAAGATGC-3', and for antisense primer
was 5'-CCTCAGGGCACTGCAGGATG-3'. GAPDH
gene was used as an internal control using the sense
primer 5'-GCACCGTCAAGGCTGAGAAC-3' and anti-
sense primer 5'-TGGTGAAGACGCCAGTGGA-3'.
Immunohistochemistry
Paraffin sections (3 μm) from samples of 164 NPC and 32
nasopharyngeal specimens were deparaffinized in 100%
xylene and re-hydrated in descending ethanol
series(100%, 90%,80%, 70% ethanol) and water according
to standard protocols. Heat-induced antigen retrieval was
performed in 10 mM citrate buffer for 2 min at 100°C.
Endogenous peroxidase activity and non-specific antigen
were blocked with peroxidase blocking reagent contain-
ing 3% hydrogen peroxide and serum, followed by incu-
bation with goat anti-human MMP9  antibody (1:100)
(Abcam, MA, USA) for 1 h at 37°C. After washing, the
sections were incubated with biotin-labeled rabbit anti-
goat antibody for 10 min at room temperature, and sub-
sequently were incubated with streptavidin-conjugated
horseradish peroxidase (HRP) (Maixin Inc, China). The
peroxidase reaction was developed using 3, 3-diamin-
obenzidine chromogen solution in DAB buffer substrate.
Sections were visualized with DAB and counterstained
with hematoxylin, mounted in neutral gum, and analyzed
using a bright field microscope.
Evaluation of staining
The immunohistochemically stained tissue sections were
reviewed and scored separately by two pathologists
blinded to the clinical parameters. The staining intensity
was scored as previously described [6,7]. The extent of
the staining, defined as the percentage of positive staining
areas of tumor cells or normal nasopharyngeal epithelial
cells in relation to the whole tissue area, was scored on a
scale of 0 to 4 as the following: 0, < 10%; 1, 10-25%; 2, 26-
50%; 3, 50-75%; and 4, >76%. The sum of the staining-
intensity and staining-extent scores was used as the final
staining score for MMP9 (0-7). For statistical analysis, a
final staining scores of 0-5 and 6-7 were respectively con-
sidered to be low and high expression.
Statistical analyses
All statistical analyses were performed using SPSS 13.0
software. Data were presented as mean ± SD. The χ2 test
was used to analyze the relationship between the levels of
MMP9 expression and clinicopathologic characteristics.
Survival curves were plotted using the Kaplan-Meier
method and compared using the log-rank test. The signif-
icances of various variables in survival were analyzed
using multivariate cox proportional hazards model. A P
value of less than 0.05 was considered statistically signifi-
cant.
Results
MMP9 mRNA was highly expressed in NPC tissue
In order to assess the role of MMP9 in NPC, we per-
formed real-time PCR to measure the expression of
MMP9 mRNA transcripts in 7 freshly collected NPC tis-
sues and 5 freshly collected normal nasopharyngeal tis-
sues. Compared with normal nasopharyngeal tissues,
NPC tissues showed higher expression levels of MMP9
mRNA with an average increase of 3.4-fold (Figure 1).
Immunohistochemical analysis of MMP9 protein expression 
in NPC and nasopharyngeal tissues
We measured the expression levels and subcellular local-
ization of MMP9  protein in 164 archived paraffin-
embedded NPC samples and 32 non-cancerous nasopha-
ryngeal samples using immunohistochemical stainingLiu et al. BMC Cancer 2010, 10:270
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(Figure 2A-E). Specific MMP9 protein staining was found
in the cytoplasm of non-cancerous and malignant epithe-
lial cells. Furthermore, we observed that in 77.4% (127/
164) of NPC samples, MMP9  protein was highly
expressed. In comparison, only 53.1% of non-cancerous
nasopharyngeal samples had highly expressed MMP9
protein, significantly lower than that in the NPC samples
(P = 0.008) (Table 1).
Relationship between clinicopathological characteristics 
and MMP9 expression in NPC patients
The relationships between clinicopathological character-
istics and MMP9  expression levels in individuals with
NPC are summarized in Table 2. We did not find a signif-
icant association of MMP9  expression levels with
patient's age, sex, smoking, tumor size (T classification),
and status of distant metastasis (M classification) in 164
N PC  c a s e s.  H o w ev e r ,  w e  o b s e rv e d  t h a t  t h e  e x p r e s s i o n
level of MMP9 was positively correlated with the status of
lymph node metastasis (N classification) (N0-N1 vs. N2-
N3) (P = 0.002), and clinical stage (I-II vs. III-IV) (P <
0.000) in NPC patients (Table 3).
Survival analysis
To investigate the prognostic value of MMP9 expression
for NPC, we assessed the association between the levels
of MMP9 expression and patients' survival using Kaplan-
Meier analysis with the log-rank test. In 164 NPC cases
with prognosis information, we observed that the level of
MMP9  protein expression was significantly correlated
with the overall survival of NPC patients (Figure 2F).
Patients with high level of MMP9 expression had poorer
survival than those with lower level of MMP9 expression
(P = 0.001). In addition, T, N, M classifications and clini-
cal stages were also significantly correlated with patients'
survival (P = 0.034, P < 0.001, P < 0.001, and P < 0.001
respectively). To determine whether MMP9 is an inde-
pendent prognostic factor for NPC, we performed multi-
variate analysis of the levels of MMP9 protein expression
adjusted for age, gender, smoking status, T classification,
N classification, M classification, and clinical stages of
NPC patients. The results showed that the level of MMP9
expression was an independent prognostic factor for
NPC (Table 4).
Discussion
NPC is a malignant neoplasm arising from the mucosal
epithelium of the nasopharynx, most often within the lat-
eral nasopharyngeal recess and has been thought to be
closely associated with Epstein-Barr virus infection,
dietary, and genetic factors. The majority of the NPC
deaths attribute to tumor metastases rather than primary
tumors. However, the molecular mechanism of NPC
invasion and metastasis remains incompletely under-
stood.
In a recent microarray analysis, we found the signifi-
cantly elevated level of MMP9 mRNA in NPC compared
to non-cancerous nasopharyngeal tissues [2]. In this
report, we found that MMP9  was expressed predomi-
nantly in the epithelial cells in both NPC and non-cancer-
ous nasopharyngeal tissues by immunohistochemistry
assay, which was consistent with Horikawa's result[8].
Similar to a report from Wong et al [9], we further pre-
sented the evidence that MMP9  was overexpressed at
both mRNA and protein levels in NPC tissues compared
to nasopharyngeal tissues, suggesting that MMP9  was
involved in the pathogenesis of NPC.
MMP9 is a Zn2+ dependent endopeptidase that medi-
ates the degradation of extracellular matrix protein [10],
and is associated with tumor invasion and metastasis
[11,12]. It is synthesized and secreted in monomeric form
as zymogen, and belongs to the gelatinase subgroup.
Increased expression of MMP9 is usually seen in invasive
and metastatic cancers such as colorectal cancer [13],
gastric carcinoma [14], pancreatic carcinoma [15], breast
cancer [16], and oral cancer [17]. The levels of MMP9
expression have also been found to be increased in nasal
Table 1: Protein expression of MMP9 between NPC and nasopharyngeal samples
Group Protein expression P value
Cases High expression Low expression
Cancer 164 127(77.4) 37 (22.6)
Normal 32 17(53.1) 15 (46.9) 0.008
Figure 1 Expression detection of MMP9 mRNA in NPCs and NPs. 
MMP9 mRNA was highly expressed in NPC tissues compared with NP 
tissues (3.4 folds).T:Tumor; N:Normal.Liu et al. BMC Cancer 2010, 10:270
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NK/T-cell lymphoma [18], malignant astrocytomas, car-
cinomatous meningitis, and brain metastases [19]. In this
study, we also found that MMP9 overexpression was sig-
nificantly associated with T classification (tumor size), N
classification (lymph node metastasis), and clinical stages
of NPC patients. Overexpressed MMP9  in NPC may
accelerate tumor growth by inducing angiogenesis and
enhance local cell invasion and metastasis by degrading
the extracellular matrix. Our results may indicate that
MMP9 plays significant roles in NPC progression, includ-
ing tumor invasion and metastasis. Similarly, Horikawa et
al also showed that overexpressed MMP9  protein was
positively correlated with lymph node metastasis of NPC
[8]. Furthermore, the expression of MMP9 also showed a
significant positive correlation with the expression of
oncoprotein  LMP1  in NPC tissues. Transfection of a
LMP1  expression plasmid into C33A cell line could
increase  MMP9  expression [20]. These studies consis-
tently suggest that overexpressed MMP9  may play an
unfavorable role in NPC pathogenesis. However, the cor-
relation between MMP9 expression and the survival of
NPC patients has been seldom reported.
In the past few years, MMP9 overexpression in tumor
cells has been shown to be an independent prognostic
factor in several types of tumors, which has a favorable or
unfavorable prognostic significance depending on tumor
types[21-24]. In epithelial ovarian cancer, the higher the
amount of MMP9 positive cancer cells, the longer was the
10-year disease-related survival (DRS) [21]. Interestingly,
similar results were reported in breast cancer. Pellikainen
found that in breast cancer, positive MMP9 expression in
cancer cells favored patient's survival [22]. On the con-
trary, there was more evidence indicating that overex-
pression of MMP9  in cancer cells was not a favorable
prognosis factor in non-small cell lung can-
cer(NSCLC)[23], colorectal cancer[24], and oesophageal
carcinoma, etc[25]. In NSCLC and colorectal cancer,
overexpressed  MMP9  was markedly associated with
Figure 2 Kaplan-Meier plots of overall survival duration in patients with NPC. MMP9 protein expression in NPC and NP samples(A-E): A:Weak 
expression of MMP9 in NP sample; B:Negative expression of MMP9 in NPC samples(original magnification 400×);C-E:Strong staining of MMP9 in NPC 
samples (original magnification 400×). F. Kaplan-Meier survival analysis of overall survival duration in 164 NPC patients according to MMP9 protein 
expression. The log-rank test was used to calculate p values.Liu et al. BMC Cancer 2010, 10:270
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shortened cancer-related survival. In oesophageal carci-
noma, MMP9 overexpression was significantly correlated
with the depth of tumor invasion, lymphatic permeation,
nodal metastasis, and pathologic differentiation grade.
In the present study, we presented the evidence that
MMP9 protein expression in NPC was inversely corre-
lated with patient's overall survival. The patients with
higher expression of MMP9 protein had shorter survival
time. According to multivariate analyses, increased
expression of MMP9 protein was a significant predictor
of poor prognosis for NPC patients, especially for its
patients at late-stage. These results were analogous to Li
et al's report[26] but inconsistent with Wong et al's inves-
tigation[9]. Li et al used immunohistochemistry assay in
NPC tissues to find that NPC patients with dual high-
expression of MMP9/PAR-2 showed a significantly worse
prognosis than those with single highly expressed protein
or dual low or negatively expressed proteins, which
strongly supported the reliability of our study. However,
Wong et al reported that the increased level of plasma
pro-MMP9 by enzyme linked immunosorbant assay did
not correlate with NPC patients' clinical outcome. The
discrepancy between our data and Wong et al's data
would be most likely due to the different samples and
method used.
Conclusion
In summary, our study demonstrated that the expression
level of MMP9 was significantly increased in NPC and
correlated with the malignant status of NPC. Further-
more, our data suggested that MMP9 was an important
prognostic factor for NPC. Yet, due to the limited sample
size of patients in our investigation, further studies would
be needed to verify these findings and establish the role
Table 2: Clinicopathologic characteristics of patient 
samples and expression of MMP9 in NPC
N (%)
Gender
Male 116 (70.7)
Female 48 (29.3)
Age (y)
<50 83 (50.6)
≥50 81 (49.4)
Smoking
Yes 39 (23.8)
No 125 (76.2)
T classification
T1-T2 116 (70.3)
T3-T4 48 (29.3)
N classification
N0-N1 74 (45.1)
N2-N3 90 (54.9)
Distant metastasis
Yes 8 (5.1)
No 156 (94.9)
Clinical stage
I~II 55 (33.5)
III~IV 109 (66.50)
Status at follow-up
Alive 102 (62.2)
Death secondary to NPC 62 (38.8)
Expression of MMP9
High expression 127 (77.4)
Low expression 37 (22.6)
Table 3: Correlation between the clinicopathologic 
characteristics and expression of MMP9 protein in NPC
MMP9 (%)
Characteristics n High 
expression
Low 
expression
P
Gender
Male 116 94(81.0) 22 (19.0)
Female 48 33(43.6) 15 (56.4) 0.102
Age( y)
≥50 81 61 (75.3) 20 (24.7)
<50 83 66 (47.7) 17(52.3) 0.577
Smoking
Yes 39 31 (79.5) 8 (20.5)
No 125 96 (76.8) 29 (23.2) 0.828
T classification
T1-T2 116 85 (73.3) 31(26.7)
T3-T4 48 42 (87.5) 6(12.5) 0.064
N classification
N0-N1 74 49 (66.2) 25 (33.8)
N2-N3 90 78 (86.7) 12 (13.3) 0.002
Distant 
metastasis
Yes 8 7 (87.5) 1 (12.5)
No 156 120 (76.9) 36 (23.1) 0.685
Clinical stage
I~II 55 30 (54.5) 25 (45.5)
III~IV 109 97 (89) 12(11) 0.000Liu et al. BMC Cancer 2010, 10:270
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of MMP9 as a reliable clinical predictor for the outcome
of NPC patients.
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